

Table IV. *Published series on patients with cervical cancer treated with stereotactic body radiation therapy boost.*

Author (ref)	Median age (range), years	Patients, n	Median FU (range), months	FIGO stage, n	Dose, Gy	Fractions	LR, n	DM, n	Survival/LC	Acute toxicity, n	Late toxicity, n
Jorcano <i>et al.</i> (16)	62 (37-74)	26	47 (4-77)	I: 17 II: 7 III: 2	7	2	2	1	3-Year FFS: 96% OS: 95%	Dyspareunia: 1 Synechiae: 1 Dryness: 4	Vaginal: dryness: 5 Synechiae: 3 Stenosis: 1
Ito <i>et al.</i> (25)	55 (49-74)	6	17 (8-32)	NA	19.5/21/22.5	3	1	1	NA	Acute diarrhea 1 Radiation dermatitis 2	Lower limb edema: 1 Vertebral: compression: 1
Mollà <i>et al.</i> (19)	53 (33-71)	16	12.6 (6-26)	I: 9 II: 6 III: 1	14/20	2/5	NA	NA	NA	Dyspareunia: 1 Synechiae: 1 Dryness: 3 Pruritus: 1	Vaginal: dryness: 5 Synechiae: 1 Rectal: bleeding: 1
Lazzari <i>et al.</i> (18)	55 (30-82)	25	26 (4-77)	IIB: 3 IIIB: 3 IIIC1: 9 IIIC2: 2 IVA: 2 IVB: 6	25	5	5	8	2-Year OS: 67% LC: 78% PFS: 55%	G1-2 Diarrhea/cystitis: 10	G1-2 Rectal bleeding/proctitis: 8
Kubicek <i>et al.</i> (15)	62 (47-81)	11	14 (NR)	NA	25 (15-27.5)*	3-5	2	0	NA	G2 GU/GI: 2	G3 GI bleeding 1
Hsieh <i>et al.</i> (20)	68 (46-93)	9	NA	IIB: 4 IIIB: 3 IVA: 2	27 (27-16)	5-9	2	4	3-Year OS: 25.9% DFS: 77.8% MFS 28.6%	G3: 2	G3: 3 G4: 1 (fistula)
Haas <i>et al.</i> (21)	80 (71-94)	6	14 (1-28)	IIB: 4 IV: 1 IVA: 1	19.5/20	3/5	NA	NA	NA	No acute toxicities	No late toxicities
Marnitz <i>et al.</i> (22)	NR (32-69)	11	6 (NR)	IIB: 8 IIIB: 2	30	5	0	0	6-Month LC: 100%	Hematological: 4	NA
This study	57 (38-79)	9	16 (6-58)	IIA: 3 IIB: 2 IIIB: 1 IIIC: 1 IVA: 2	18 (15-25)*	3-5	1	2	2-Year OS 70%	G1 Bladder: 2 G1 GI: 1	G1: 2 G2: 1 G3: 1

DFS: Disease-free survival; DM: distant metastasis; FFS: failure-free survival; G: grade; GU: genitourinary; GI: gastrointestinal; LC: local control; LR: local relapse; MFS metastases-free survival; NA: not assessed; NR: not reported; OS: overall survival; PFS: progression-free survival. *Median (range) of total dose.